Drug Profile


Alternative Names: RDEA-3170

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; AstraZeneca
  • Class Antigouts; Naphthalenes; Propionic acids; Pyridines; Small molecules
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Hyperuricaemia; Kidney disorders; Type 2 diabetes mellitus

Most Recent Events

  • 24 Oct 2017 AstraZeneca plans a phase II trial for Hyperuricaemia (Combination therapy) in USA (NCT03316131)
  • 14 Jun 2017 Updated pharmacokinetics data from a phase I trial in Gout and Hyperuricaemia presented 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 14 Jun 2017 Updated pharmacokinetics and adverse events data from a phase II trial in Gout presented 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top